Different effects of total flavonoids from Arachniodes exilis on human umbilical cord mesenchymal stem cells in vitro

Wenmin Yu, PhD, Wenlong Hu, MS, Xiumei Ke, MS, Xufeng Zhou, MS, Changchang Yin, PhD, Ming Yin, PhD

Abstract

Traditional Chinese medicines are used in promotion of fractured bone healing and bone diseases. Some studies reported total flavonoids from plant can be used as an auxiliary source of exogenous.

Use different methods to identify and verify effects of total flavonoids from Arachniodes exilis (TFAE) on human umbilical cord mesenchymal stem cells (HUCMSCs) in vitro.

Concentrations of 1 and 5 μg/mL TFAE significantly increased ALPase activity in HUCMSCs compared to the other concentrations at days 3 and 7 (P < .05). RT-PCR showed that expression levels of osteogenic genes (Col1a1, OPN, Runx2 and Osx) were remarkably enhanced in HUCMSCs following treatment with different concentrations of TFAE for 9 days compared with 0 μg/mL TFAE group (control). The results showed that concentration < 5 μg/mL of TFAE induced osteogenic differentiation in HUCMSCs Alizarin red staining assays revealed that both TFAE and S1191 was significantly decreased (7.80 ± 0.66) compared with the TFAE group (16.00 ± 0.97) (P < .01). ALPase activity on days 3 and 7 was relatively lower in HUCMSCs grown in media supplemented with both S1191 and TFAE than that of in TFAE group only. The results indicated that osteogenic markers (Col1a1, OPN, Runx2 and Osx) were significantly downregulated in the TFAE + S1191 group in comparison to the control group. The expressions of Col1a and OPN in the TFAE + S1191 group decreased significantly (P < .01) by Western blotting.

TFAE promotes the odonto/osteogenic differentiation of human UCMSVs via activation of ER.

Abbreviations: HUCMSCs = human umbilical cord mesenchymal stem cells, TCMs = traditional Chinese medicines, TFAE = total flavonoids from Arachniodes exilis.

Keywords: alizarin red S staining, estrogen receptor, human umbilical cord mesenchymal stem cells, osteogenic, traditional Chinese medicines.

1. Introduction

Traditional Chinese medicines (TCMs) are used in promotion of fractured bone healing and bone diseases such as osteoporosis.[1] Many studies have shown the positive effects of TCM on bone formation in vitro and in vivo.[2] The study showed that several TCMs have bone promoting properties, The mechanism of this may be due to the angiogenic effects.[3]

Recently, some scholars reported the role of total flavonoids in anti-cancer and osteogenic differentiation. Zhou et al found that

* The School of Basic Medical Science, Jiujiang University/Jiujiang Key Laboratory of Translational Medicine, Jiujiang, Correspondence: Changchang Yin, The School of Basic Medical Science, Jiujiang University/Jiujiang Key Laboratory of Translational Medicine, Jiujiang, Jiangxi, P. R. China; 320 XunYang East Road, Jiujiang 332000, Jiangxi, P. R. China (e-mail: yinchangchang112@163.com); Ming Yin, Medicine Graduate School of Nanchang University, Nanchang, 330006, P. R. China (e-mail: yinhm0791@aliyun.com).

** The School of Basic Medical Science, Jiujiang University/Jiujiang Key Laboratory of Translational Medicine, Jiujiang, Jiangxi, P. R. China; 320 XunYang East Road, Jiujiang 332000, Jiangxi, P. R. China (e-mail: yinchangchang112@163.com); Ming Yin, Medicine Graduate School of Nanchang University, Nanchang, 330006, P. R. China (e-mail: yinhm0791@aliyun.com).

© Copyright 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. How to cite this article: Yu W, Hu W, Ke X, Zhou X, Yin C, Yin M. Different effects of total flavonoids from Arachniodes exilis on human umbilical cord mesenchymal stem cells in vitro. Medicine 2020;99:25(e20628).

Editor: Daryle Wane.

Received: 11 February 2020 / Received in final form: 6 May 2020 / Accepted: 8 May 2020
ethanol extracts from Arachniodes exilis have anti-oxidant and hepato-protective roles and could potentially be used in the treatment of liver disease.[4] We previously reported that total flavonoids from arachniodes exilis (TFAE) enhances the osteogenic capacity of mesenchymal stem cells via BMP signaling.[5] The roles of flavonoids and polyphenol derivatives of these extracts have been studied, but the biological effects of various extracts are not clear. The study showed that TFAE mediates apoptosis in HepG2 cells by activating MAPK signaling, but the proliferation effect of LO2 cells is not obvious at appropriate concentrations.[6] Some researchers proved that flavonoids derived from epimedium pubescens can promote the differentiation of rat bone marrow mesenchymal stem cells into bone cells,[7] others found that epimedium pubescens flavonoids promotes MC3T3-E1 cell proliferation and osteogenic differentiation by activating ERK-JNK signaling mediated by the estrogen receptor (ER).[8] The study showed estrogen promotes early osteoblast differentiation.[9] Little is known about the direct impact of TFAE on human umbilical cord mesenchymal stem cells (HUCMSCs).

TCM have been used in the Chinese population for the treatment of bone diseases and in promoting bone healing for thousands of years.[10] Shalan NA et al reported Noni leaf and black tea enhance bone regeneration in estrogen-deficient rats.[11] If TCMs are found to promote bone formation, these can be used in bone grafting materials that could eliminate or decrease the need to use allografts, which may be a source of transmission of disease. In this study, we present evidence that TFAE induces osteogenic differentiation of HUCMSCs. Our study provides support for the use of exogenous growth factors as remedies that could potentially be used to treat bone defects.

2. Materials and methods

2.1. Isolation and culture of HUCMSCs

The research protocol was approved by the ethics committee of the School of Basic Medical Science at Jiujiang University and by the Jiujiang Maternal and Child Health Hospital. Informed consent was obtained from delivering mothers. Umbilical cords (UCs) were processed within 24 hours after delivery. Adherent cells were cultured and isolated using the explant method. Briefly, HUCMSCs were longitudinally dissected from the UC, separating them from the Wharton’s jelly tissue coating. HUCMSCs were isolated and cultured following the manufacturer’s instructions (Cyagen Biosciences Inc, America).

2.2. Identification of HUCMSCs

HUCMSCs were assessed by flow cytometry to identify typical cell surface epitopes (CD19, CD29, CD90, and CD105). Briefly, HUCMSCs were incubated for 30 minutes at 4°C with the following mouse monoclonal antibodies: phycoerythrin (PE)-conjugated CD29 (No. ab24697 Abcam, UK), CD90 (No. ab3105 Abcam, UK) and CD105 (No. ab11414 Abcam, UK), and fluorescein isothiocyanate (FITC)-conjugated CD19 (ab24936 Abcam, UK). As isotypic controls, we used PE- and FITC-conjugated anti-mouse IgG antibodies (ab6785 Abcam, UK). Dead cells were identified by staining with propidium iodide and excluded from surface epitope analyses. Cells were analyzed with FlowJo software (Tree Star, Inc., Ashland, OR).

2.3. Preparation of TFAE and determination of the total flavonoids content

TFAE was prepared in Jiujiang Key Laboratory of Translational Medicine (China) according to a previously published method.[9] The roots of A. exilis were collected from Lushan city, Jiangxi province, China. A voucher specimen (No. F1205) has been deposited in the Jiujiang Key Laboratory of Translational Medicine, Jiujiang, Jiangxi, P. R. China. Determination of the Total Flavonoids Content in TFAE. The total flavonoids in TFAE were estimated as rutin equivalent. Briefly, a series of rutin solutions in the concentration range of 0 to 65.0 µg/mL were used for the calibration curve and were prepared as below: 25 mL of rutin samples at certain concentrations was prepared by step by step mixing appropriate volumes of rutin stock solution with 1 mL of 5% (w/v) NaNO2 solution, 1 mL of 10% Al(NO3)3 solution, and 10 mL of a 10% (w/v) NaOH solution, and after each adding, the mixtures were allowed to stand for 6 min. Finally, the mixtures were made up to 25 mL with distilled water and mixed well. The absorbance was measured with a spectrometer (Purkinje General Instrument Co., Ltd, Beijing, China) at 515 nm. Similarly, the TFAE sample was prepared and analyzed as above. On the basis of the calibration curve, the total flavonoids content of TFAE was calculated.

2.4. Proliferation of HUCMSCs

A CCK-8 assay was performed to detect the effect of TFAE on the viability of HUCMSCs. For this assay, cells were seeded in 96-well plates at 5 × 103 cells/well. After 24 hours, cells were treated with different concentrations of TFAE (1 µg/mL, 5 µg/mL, 10 µg/mL, or 20 µg/mL) for 24 hours, 48 hours, and 72 hours. Control cells were cultured in DMEM/F12 not supplemented with TFAE. 10 µL CCK-8 assay reagent was added to each well, and the plate was incubated for 2 h at 37°C. The absorbance (A) at 450 nm was recorded for each well using a microplate reader. Cell viability (%) was calculated.

2.5. Osteogenic differentiation of HUCMSCs with treatment of TFAE and S1191

HUCMSCs were seeded at 3 × 104 cells/cm² in 6-well plates pre-coated with a gelatin solution. After 24 h, cells were treated with different concentrations of TFAE. An osteogenic differentiation medium from the Human Umbilical Cord Mesenchymal Stem Cell Osteogenic Differentiation Basal Medium kit (HUXUC-90021, Cyagen Biosciences Inc) was used. This medium consisted of DMEM/F12 base medium (Guangzhou Cyagen Biosciences Inc) supplemented with 10% fetal bovine serum (Human Umbilical Cord Mesenchymal Stem Cell Osteogenic Differentiation Fetal Bovine Serum, Guangzhou Cyagen Biosciences Inc), penicillin-streptomycin (100 units/mL and 100 µg/mL, respectively, Guangzhou Cyagen Biosciences Inc), 10 mM dexamethasone (Guangzhou Cyagen Biosciences Inc), 10 mM β-glycerophosphate (Guangzhou Cyagen Biosciences Inc), and 50 µg/mL Ascorbate (Guangzhou Cyagen Biosciences Inc). Four treatment groups were analyzed in triplicate: a control group (cultured in DMEM/F12 not supplemented with the osteogenic differentiation medium), a 0 µg/mL TFAE group (cultured in the osteogenic differentiation medium not supplemented with TFAE), a 1 µg/mL TFAE group (cultured in the osteogenic differentiation medium supplemented with 1 µg/mL TFAE), and...
a 5 μg/mL TFAE group (cultured in the osteogenic differentiation medium supplemented with 5 μg/mL TFAE). The 0 μg/mL TFAE group was used as a positive control.

To determine the potential involvement of ER in TFAE-mediated osteogenic differentiation of HUCMSCs, we used the ER inhibitor S1191. Four treatment groups were analyzed in triplicate: a 0 μg/mL TFAE group (cultured in the osteogenic differentiation medium not supplemented with TFAE), a 5 μg/mL TFAE group (cultured in osteogenic differentiation medium supplemented with 5 μg/mL TFAE), a 5 μg/mL TFAE+S1191 group (cultured in the osteogenic differentiation medium supplemented with 5 μg/mL TFAE and S1191 (Sigma-Aldrich, USA), and an S1191 group (cultured in osteogenic differentiation medium supplemented with S1191). Media was changed every 3 days. Osteogenic differentiation medium without the TFAE supplement was used as control.

2.6. Alizarin red S staining

Alizarin red S staining was performed to determine bone nodule formation. After 10 days of treatment, cells were washed twice with 1 x PBS and then fixed with 4% formaldehyde solution for 30 minutes. Next, cells were washed twice with 1 x PBS and stained with 1 mL alizarin red solution for 5 minutes. Lastly, cells were rinsed 3 times with 1 x PBS and visualized and imaged under a microscope.

2.7. Alkaline phosphatase activity (ALP)

An ALP assay kit (Maccura Biotechnology Co., Ltd. China, No: CH0101203) was used to determine alkaline phosphatase activity. After 3 or 7 days of treatment, media was aspirated off the cells, 0.5 ml 0.1% TritonX-100 was added to the cells, and then, the cell lysate was collected using the ALP assay kit according to the manufacturer’s recommended protocol. Absorbance values (OD) were recorded at 450 nm, the average absorbance values (ΔA/min) were determined, and ALP activity was calculated as follows: ALP(DU/L) = ΔA/min × 2713.

2.8. RNA extraction and RT-PCR analysis

Cells were collected at the appropriate times as described above. Total RNA was extracted using the GREEN spin tissue/cell RNA rapid extraction kit (Zomanbio, China) according to the manufacturer’s recommended protocol. The reverse transcriptase polymerase chain reaction was carried out using the HiFiScript 1st Strand cDNA Synthesis Kit (Cwbitech, China No. 00081309). Briefly, 2 μg of RNA was incubated with a DNTP mixture and oligo (dT) primers at 65°C for 5 min for denaturation and annealing, samples were reverse-transcribed at 42°C for 15 min, and the reverse transcriptase was inactivated at 95°C for 5 min. Synthesized cDNA was amplified by PCR in the presence of primer pairs specific to genes expressed during differentiation. Reaction mixtures (25 μl total) contained 100 ng of cDNA,

![Figure 1. Morphological features of cultured cells derived from human umbilical cord. A. HUCMSCs at primary cultured for 5 d. B. HUCMSCs at primary cultured for 12 d. C. HUCMSCs at passage 1 cultured for 2 d. D. HUCMSCs at passage 3 cultured for 3 d. HUCMSCs = human umbilical cord mesenchymal stem cells.](image-url)
12.5 μl of SinoBio 2× Taq Master Mix and 0.4 μM primers. Primers used in the experiment were as follows: Col1a1, 5'-CAGCACAGACTTGAGGAG-3' (reverse); OPN, 5'-ACACATATGATGGCCGAGGTGA-3' (forward) and 5'-GTCGAGGTAGTTCCTCGTCTGTA-3' (reverse); Osx, 5'-AGCAGAAACGGTTGAACCCATATAAC-3' (forward) and 5'-GCTGCAAGCTCTCCATAACC-3' (reverse); Runx2, 5'-CCACCTCTGCTTTCTTGCCT-3' (forward) and 5'-GACTGGCTGGGGCTTGTAATTAA-3' (reverse); ERα, 5'-TGCAAGGAGACTGCGGCTTTGATTCT-3' (forward) and 5'-AGGCTGTTGCTCATACCTCTCT-3' (reverse). GAPDH was used as a control. Primers for GAPDH were: 5'-AGGTCGGAGTAACGTCGCTA-3' (forward) and 5'-AGGCTGTTGCTCATACCTCTCT-3' (reverse). The PCR products were separated by electrophoresis on 2.0% agarose gels.

2.9. Western blot
The cells were lysed with immunoprecipitation assay buffer containing protease inhibitors. The protein concentrations were examined using the BCA Protein Assay kit (Vazyme Biotech, China). 40 μg of proteins were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a piece of polyvinylidene difluoride membrane. The membranes were blocked with 5% non-fat milk in TBST (Tris-buffered saline with 0.5% of Triton X-100) for 1 hour at room temperature, and then incubated with the appropriate primary antibody against Col1α1 (No.ab21286 Abcam) and OPN (No. ab75285 Abcam) or GAPDH (No. 10494-1-AP Proteintech, China) overnight at 4°C. The membranes were washed 3 times in TBST, followed by incubation with the appropriate horseradish peroxidase-linked secondary antibodies (No. 10285-1-AP Proteintech, China) for 1 hour at room temperature. The specific proteins on the blots were developed with enhanced chemiluminescence (Vazyme Biotech, China) and visualized as the bands on the CL-XPosure Film (Thermo Fisher Scientific).

2.10. | Statistical analysis

Statistical analyses were performed using the SPSS 19.0 statistical software package (SPSS Inc.). The data was expressed as the mean ± standard deviation (SD). Differences between groups were analyzed using the Student t-test or 1-Way ANOVA. \( p < .05\) was considered to be statistically significant.

3. Results

3.1. Isolation and culture of HUCMSCs

HUCMSCs migrated from the adherent UC tissue fragments after 3 to 5 days. We successfully isolated HUCMSCs from UCs after culturing for 10 to 14 days. The cells displayed similar fibroblast-like spindle-shaped morphology and were not significantly different from the source material (Fig. 1A–D).

3.2. Identification of HUCMSCs

HUCMSCs at passage 5 were dissociated using pancreatin, stained with isotype controls and labeled with antibodies against CD19, CD29, CD90, and CD105 for flow cytometry. The results showed that over 95% of the cells were positive for the CD90, CD29, and CD105 surface markers. Over 98% of the cells were negative for CD19 (Fig. 2).

3.3. The effect of TFAE on proliferation of HUCMSCs

The effect of TFAE on the proliferation of HUCMSCs was evaluated using the CCK-8 assay. Cell viability was also examined using the CCK-8 assay. The viability reflected the
metabolic activity of living cells, and the data was expressed as a percentage of the untreated control. HUCMSCs were treated with TFAE (1 μg/mL, 5 μg/mL, 10 μg/mL, or 20 μg/mL) for 24 hours, 48 hours, and 72 hours. The results indicated that concentrations of TFAE > 5 μg/mL significantly inhibited cell proliferation (P < .05), while concentrations of TFAE < 5 μg/mL significantly promoted the proliferation of HUCMSCs (Fig. 3A).

3.4. Effects of TFAE on osteogenic differentiation of HUCMSCs

To study the effect of different concentrations of TFAE on osteogenic differentiation of HUCMSCs, cells were treated with TFAE (1 μg/mL, 5 μg/mL, 10 μg/mL, or 20 μg/mL) for 24 hours, 48 hours, and 72 hours. The results indicated that concentrations of TFAE > 5 μg/mL significantly inhibited cell proliferation (P < .05), while concentrations of TFAE < 5 μg/mL significantly promoted the proliferation of HUCMSCs (Fig. 3A).
osteogenic genes (Col1a1, OPN, Runx2 and Osx) were remarkably enhanced in hUCMSCs following treatment with different concentrations of TFAE for 9 days compared with 0 μg/mL TFAE group (control). In particular, expression levels of Col1a1, OPN, Runx2 and Osx in HUCMSCs treated with 5 μg/mL TFAE were significantly higher on day 9 than those of 0 μg/mL TFAE group (control). Expression levels of Col1a1, OPN, Runx2 and Osx could be upregulated by treatment with as little as 5 μg/mL (Fig. 4B, C).

Western blotting was employed to detect HUCMSC Col1a1 and OPN protein levels 7 days after treatment with different concentrations of TFAE (1 μg/mL and 5 μg/mL). Col1a1 and OPN protein levels were significantly higher on day 9 than those of 0 μg/mL TFAE group (control). Expression levels of Col1a1, OPN, Runx2 and Osx could be upregulated by treatment with as little as 5 μg/mL (Fig. 4B, C).

To determine the involvement of ER potential in TFAE-mediated osteogenic differentiation of HUCMSCs, we investigated the effects of an inhibitor of ER (S1191, a special inhibitor of ER) on osteogenic differentiation of HUCMSCs by Alizarin red S staining, ALP activity assays and analysis of expression levels of odonto/osteogenic genes. Calcification levels in HUCMSCs treated with TFAE for 10 days were identified by alizarin red staining. Four groups were included in the staining assays: a control group (0 μg/mL TFAE), a TFAE group (5 μg/mL TFAE), a TFAE+S1191 group (5 μg/mL TFAE) and an S1191 group (0 μg/mL TFAE). Alizarin red staining assays revealed that staining in the TFAE group (16.00±0.97) was higher than in the control group (4.80±0.41) and that the staining in hUCMSCs treated with both TFAE and S1191 was significantly decreased (7.80±0.66) compared with the TFAE group (16.00±0.97) (P<.01).

3.5. Estrogen receptor(ER) involvement in TFAE-mediated osteogenic differentiation of HUCMSCs

To determine the involvement of ER potential in TFAE-mediated osteogenic differentiation of HUCMSCs, we investigated the effects of an inhibitor of ER (S1191, a special inhibitor of ER) on osteogenic differentiation of HUCMSCs by Alizarin red S staining, ALP activity assays and analysis of expression levels of odonto/osteogenic genes. Calcification levels in HUCMSCs treated with TFAE for 10 days were identified by alizarin red staining. Four groups were included in the staining assays: a control group (0 μg/mL TFAE), a TFAE group (5 μg/mL TFAE), a TFAE+S1191 group (5 μg/mL TFAE) and an S1191 group (0 μg/mL TFAE). Alizarin red staining assays revealed that staining in the TFAE group (16.00±0.97) was higher than in the control group (4.80±0.41) and that the staining in hUCMSCs treated with both TFAE and S1191 was significantly decreased (7.80±0.66) compared with the TFAE group (16.00±0.97) (P<.01).
The expression levels of Col1a1 and OPN were significantly increased in the TFAE group compared with the control group ($P<0.01$). Compared with the TFAE group, the expressions of Col1a1 and OPN in the TFAE+S1191 group decreased significantly ($P<0.01$). However, there was no difference between the control group and the S1191 group. These results demonstrate that ER is involved in TFAE-mediated osteogenic differentiation of HUCMSCs (Fig. 8A, B).

3.6. Effect of ER inhibitor on ER expression in TFAE-mediated osteogenic differentiation of HUCMSCs

Since TFAE has been shown to promote the osteogenic differentiation of HUCMSCs further examined the effect of the ER inhibitor (S1191) on TFAE-mediated osteogenic differentiation of HUCMSCs. We observed the effects of TFAE on the mRNA expression of ERα and ERβ in TFAE-mediated odonto/osteogenic differentiation of HUCMSCs. The results showed that there was no significant effect of TFAE on ERα and ERβ mRNA expression levels after the cells treated with 1 or 5 μg/mL TFAE, which suggested that TFAE does not change the mRNA expressions of ERα and ERβ, and that the ER protein is involved in TFAE-mediated osteogenic differentiation of HUCMSCs (Fig. 8C, D).

4. Discussion

In recent years, human umbilical cords have become an attractive source of mesenchymal stem cells (MSCs) for tissue regeneration because of no ethical considerations. MSCs are considered a promising therapeutic tool for diseases including heart failure, kidney injury, and myasthenia gravis. We previously reported that TFAE enhances the osteogenic capacity of mesenchymal stem cells. The potential beneficial biological effects of dietary flavonoids should obviously be a key concept in studies of these compounds. However, the effects of TFAE on the osteogenic differentiation of HUCMSCs is unclear. Although effects of flavonoids have been extensively studied in vitro and in vivo, this study is the first to demonstrate that TFAE promotes the differentiation of HUCMSCs into bone cells.

In the present study, high TFAE concentrations (>$10 \mu g/mL$) significantly inhibited proliferation of HUCMSCs, while low concentrations of TFAE regulated cell proliferation in a dose-dependent manner. To elucidate the effects of TFAE on the osteogenic differentiation of HUCMSCs, we used TFAE at a concentration ≤$5 \mu g/mL$ to stimulate differentiation of HUCMSCs in vitro. Under such conditions, HUCMSCs can retain a stable capacity for growth, guaranteeing sustainable differentiation and enhancing ALP activity as well as the odonto/osteogenic potential of the HUCMSCs without affecting their proliferation. As osteoblastic-specific markers, Runx2 and Oss are early-stage markers of osteoblastic differentiation, and the expressions of Runx2 and Oss have been found to be increased in TFAE-treated HUCMSCs, indicating that TFAE concentration under 5 μg/mL promote osteoblastic differentiation. Runx2 overexpression can induce the differentiation of MSCs into osteoblast lineages in vitro, while Oss is highly expressed in functional odonto/osteoblasts. Thus, upregulation of Runx2 and Oss in HUCMSCs after TFAE treatment ($>5 \mu g/mL$) suggests that TFAE induces the biological differentiation changes in HUCMSCs. Our results are consistent with previous reports. Col1a1 and OPN are considered to be end-stage markers of bone formation, closely related to bone
The upregulation of Col1a1 and OPN further suggested that TFAE promotes the differentiation of HUCMSCs into bone cells. Western blotting for Col1a1 and OPN confirmed these observations.

Understanding the effects of TFAE on the differentiation of HUCMSCs provides us with the opportunity to explore the molecular mechanisms of TFAE-mediated osteoblastic differentiation. Okazaki et al. reported that estrogen can promote the differentiation of rat BMSCs through ER. Studies have found that some plant sources of phytoestrogens have the same effect as estrogen did. Some flavonol compounds have a phytoestrogens effect. Song et al. found that epimedium promotes MC3T3 E1 cell proliferation and can be mediated by ER via activation of ERK and JNK signaling pathways, promoting osteogenesis differentiation.

In this study, we found that a specific ER inhibitor (S1191) can reverse the osteogenic differentiation of HUCMSCs caused by TFAE treatment. The results of Alizarin red S staining and ALP activity assays suggest that ER is activated in TFAE-treated HUCMSCs. Furthermore, inhibition of ER by S1191 treatment dramatically suppressed the mRNA expressions of the odonto/osteogenic markers Runx2, Osx, Col1a1, and OPN. To this regard, we next analyzed protein levels of the osteogenic Col1a1 and OPN after ER suppression by S1191. The results were consistent with the results of the mRNA analyses. Some reports have shown that S1191 competitively inhibits binding of oestradiol to the ER. S1191 blocks nuclear localization of ER by impairing receptor dimerization and binds to ER leading to decreased ERα stability and increases turnover of the ERα protein through enhanced proteasomal degradation. In addition, S1191 down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. It is interesting to note the effects of S1191 on the expression of osteogenic markers in this study. These data suggest that ER is involved in TFAE-mediated osteogenic differentiation of HUCMSCs. However, we found that mRNA expression level of ER was not affected in TFAE-treated HUCMSCs. Some studies indicated that flavonoids may reduce estrogen receptor binding capacity by binding to nuclear type II estrogen binding sites. Studies have reported that the majority of ER α and β are found in the cytoplasm and nucleus. The cytoplasmic estrogen–ER complex translocates into the nucleus and binds to estrogen response elements located in the target gene promoters, stimulating gene transcription. Our results indicate that the binding of ER to TFAE influences gene transcription in TFAE-mediated osteogenic differentiation of HUCMSCs but that TFAE
does not affect ER expression at the mRNA level. Further investigation of interactions between TFAE and ER is warranted. Although the underlying mechanism remains unclear, this information may provide new insights. Based on the present findings, it can be inferred that ER plays a pivotal role during committed differentiation of TFAE-treated HUCMSCs.

5. Conclusions

TFAE promotes the odonto/osteogenic differentiation of human UCMSCs via activation of ER. The findings provides a strong evidence that the therapeutic application of TFAE results in the HUCMSCs’ osteogenic differentiation. Further studies are warranted to investigate other potential mechanisms associated with TFAE-mediated osteogenic differentiation of HUCMSCs.

Author contributions

Conceptualization: Wenmin Yu and Wenlong hu.
Data curation: Wenmin Yu.
Funding acquisition: Changchang Yin and Ming Yin.
Project administration: Changchang Yin and Ming Yin.
Software: wenmin yu.
Supervision: Changchang Yin.
Writing – original draft: Wenmin Yu.
Writing – review & editing: Changchang Yin and Ming Yin.

References

[1] YC LYF Effect of Gegen on proliferation of HUVEC304 cells. Traditional Chin Med Pharm 2004;11:448–9.
[2] Wong RW, Rabie AB. Traditional Chinese medicines and bone formation – a review. J Oral Maxillofac Surg 2006;64:828–37.
[3] Yang Y, Chen A, Zhang L, et al. The role of traditional Chinese medicines in osteogenesis and angiogenesis. Phytother Res 2014;28:1–8.
[4] Zhou D, Ruan J, Cai Y, et al. Antioxidant and hepatoprotective activity of ethanol extract of Arachniodes exilis (Hance) Ching. J Ethnopharmacol 2010;129:232–7.
[5] Hu WL, Li C, Li X, et al. Total flavonoids from arachniodes exilis enhance osteogenic capacity of mesenchymal stem cells via BMP signaling. Journal of Chinese Medicinal Materials 2016;39:150–4.
[6] Li H, Chen J, Xiong C, et al. Apoptosis induction by the total flavonoids from arachniodes exilis in HepG2 cells through reactive oxygen species-mediated mitochondrial dysfunction involving MAPK activation. Evid Based Complement Alternat Med 2014;2014:906941.
[7] Wu Y, Xia L, Zhou Y, et al. Ikarin induces osteogenic differentiation of bone mesenchymal stem cells in a MAPK-dependent manner. Cell Prolif 2015;48:375–84.
[8] Song L, Zhao J, Zhang X, et al. Ikarin induces osteoblast differentiation, proliferation, and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur J Pharmacol 2013;714:15–22.
[9] Okazaki R, Ikeda T, Shiba M, et al. Ikarin promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 2002;143:2349–56.
[10] Wang SJ, YW, Rahman K, Xin HL, et al. Mechanism of treatment of kidney deficiency and osteoporosis is similar by traditional chinese medicine. Curr Pharm Des 2016;22:312–20.
[11] Shalan NA, Mohamed S. Noni leaf and black tea enhance bone regeneration in estrogen-deficient rats. Nutrition 2017;33:42–51.
[12] Weiss ML, Medcetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cells 2006;24:781–92.
[13] Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 2004; 22:1330–7.
[14] Walla T. Absorption and metabolism of flavonoids. Free Radic Biol Med 2004;36:829–37.
[15] Komori T. Regulation of osteoblast and odontoblast differentiation by RINX2. Journal of Oral Biosciences 2010;52:22–5.
[16] Pi N, Fu S, Fan M, et al. Preparation of poly (ethylene glycol)/polylactide hybrid fibrous scaffolds for bone tissue engineering. Int J Nanomedicine 2011;6:3063–75.
[17] Wade-Gerye NM, Boudiffa M, Vanden-Bosche A, et al. Absence of bone sialoprotein (BSP) impairs primary bone formation and resorption: the narrow ablation model under PTH challenge. Bone 2012;50:1064–73.
[18] Takahashi T. Overexpression of Runx2 and MKP-1 stimulates transdifferentiation of T3–1 L1 preadipocytes into bone-forming osteoblasts in vitro. Calcif Tissue Int 2011;88:336–47.
[19] Zhang J, Tu Q, Grosschedl R, et al. Roles of SATB2 in osteogenic and bone regeneration. Tissue Eng Part A 2011;17: 1767–76.
[20] Catt LA, Hollinger JO, Campbell PG. Oss traductional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem 2003;95:518–28.
[21] Yao Li MY, Zilu Wang, Yangyu Zheng, et al. 17 beta-estradiol promotes the odonto/osteogenic differentiation of stem cells from apical papilla via mitogen-activated protein kinase pathway. Stem Cell Res Ther 2014;5:125.
[22] Okazaki R, Inoue D, Shibata M, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor alpha or beta. pdf. Endocrinology. 2002;143:2349–56.
[23] Schilling T, Ebert R, Raaimakers N, et al. Effects of phytoestrogens and other plant-derived compounds on mesenchymal stem cells, bone maintenance and regeneration. J Steroid Biochem Mol Biol 2014; 139:252–61.
[24] Kim YJ, Bae YC, Suh KT, et al. Quercetin, a flavonoid, inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells. Biochem Pharmacol 2006;72:1268–78.
[25] Wakeling AE, DM, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867–73.
[26] Preiser-Mashek MT, Solodin N, Stark BL, et al. Tyrre ETA. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am J Physiol Endocrinol Metab. 2002;282: E891–8.
[27] Stenoien DL, PM, Mancini MG, Dutertre M, et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. Nature Cell Biol 2001;3:15–23.
[28] Bhattacharyya RS, Fulvestrans (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP and PC-3 human prostate cancer cells. Mol Cancer Ther 2006;5:1539–49.
[29] Markaverich BM, Alejandro RR, Johnson MA, et al. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J Steroid Biochem 1998;30:71–8.
[30] Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. Scientific World Journal 2013;2013:1–6.
[31] Lorenzo J. A new hypothesis for how sex steroid hormones regulate bone mass. J Clin Invest 2003;111:1641–7.
[32] Marino M, Pellegrini M, La Rosa P, et al. Susceptibility of estrogen receptor rapid responses to xenoestrogen interactions. Steroids 2012;77:910–7.